ClinicalTrials.gg
Active, not recruitingNCT00544115Updated Jun 2, 2026Results posted

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

A Phase 2 interventional study of busulfan and cyclophosphamide in Chronic Myeloproliferative Disorders, Graft Versus Host Disease and Leukemia, sponsored by City of Hope Medical Center. Active, not recruiting. Open to participants aged 0 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 11 months after the study started (first participant enrolled Oct 2001, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
0 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies testing busulfan in Myeloproliferative Disorders — 4 open to participants now, 6 under way, none of them phase 3. Busulfan · Myeloproliferative Disorders.

Enrollment
4th of 31
260 · median 54
Started
2001
the only one that year
Phase 2
25 of 34
4 open now
Registered
18th of 34
by date

Among the 34 studies testing busulfan in Myeloproliferative Disorders, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2001, is one of 25 in phase 2, and was the 18th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

4 of the 34 studies testing busulfan in Myeloproliferative Disorders are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About busulfan

Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 0 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing busulfan in Myeloproliferative Disorders, or all of them as a file.
02

Study summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus, methotrexate, cyclosporine, mycophenolate mofetil, and sirolimus before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works in treating patients with advanced hematologic cancer or other disorders.

Read the detailed description

OBJECTIVES:

Primary

  • To evaluate hematopoietic recovery, using neutrophil and platelet engraftment as the primary criterion, in patients with advanced hematologic malignancies or other disorders undergoing allogeneic peripheral blood stem cell (PBSC) transplantation from matched unrelated donors.
  • To evaluate the incidence of acute and chronic graft-versus-host-disease (GVHD) in patients undergoing allogeneic PBSC transplantation from matched unrelated donors.

Secondary

  • To evaluate the impact of HLA class I and class II allele-matching on the incidence of GVHD and on the survival outcome of these patients.
  • To evaluate overall survival, disease-free survival, and relapse in these patients.

OUTLINE: Patients are stratified according to type of conditioning regimen (myeloablative vs reduced-intensity myeloablative). Patients are assigned to a conditioning regimen according to diagnosis, age, disease status, prior radiotherapy, and prior autologous stem cell transplantation.

  • Conditioning regimen:

    • Regimen I: Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
    • Regimen II: Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
    • Regimen III: Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
    • Regimen IV: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
    • Regimen V: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
    • Regimen VI: Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
  • Allogeneic peripheral blood stem cell (PBSC) transplantation: All patients undergo allogeneic PBSC transplantation on day 0.
  • Graft-versus-host disease (GVHD) prophylaxis: Patients receive one of the following GVHD prophylaxis regimens:

    • Regimen A: Patients receive tacrolimus IV or orally on days -1 to 180 and methotrexate IV on days 1, 3, 6, and 11.
    • Regimen B: Patients receive cyclosporine IV or orally twice daily on days -1 to 180, mycophenolate mofetil IV over 2 hours or orally twice daily on days 0-27, and methotrexate IV on days 1, 3, and 6.
    • Regimen C: Patients receive tacrolimus IV continuously or orally, and oral sirolimus beginning on day -3. Patients also receive methotrexate IV on days 1, 3, and 6.

After completion of study therapy, patients are followed periodically.

03

Conditions studied

  • Chronic Myeloproliferative Disorders
  • Graft Versus Host Disease
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Diseases
  • Precancerous/Nonmalignant Condition

Keywords

  • graft versus host disease
  • recurrent adult acute lymphoblastic leukemia
  • recurrent childhood acute lymphoblastic leukemia
  • untreated adult acute lymphoblastic leukemia
  • untreated childhood acute lymphoblastic leukemia
  • de novo myelodysplastic syndromes
  • previously treated myelodysplastic syndromes
  • secondary myelodysplastic syndromes
  • refractory anemia with excess blasts in transformation
  • refractory anemia with excess blasts
  • atypical chronic myeloid leukemia
  • chronic myelomonocytic leukemia
  • juvenile myelomonocytic leukemia
  • myelodysplastic/myeloproliferative disease, unclassifiable
  • recurrent adult acute myeloid leukemia
  • recurrent childhood acute myeloid leukemia
  • adult acute myeloid leukemia in remission
  • childhood acute myeloid leukemia in remission
  • secondary acute myeloid leukemia
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(15;17)(q22;q12)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • accelerated phase chronic myelogenous leukemia
  • blastic phase chronic myelogenous leukemia
  • childhood chronic myelogenous leukemia
  • chronic phase chronic myelogenous leukemia
  • relapsing chronic myelogenous leukemia
  • chronic eosinophilic leukemia
  • chronic idiopathic myelofibrosis
  • chronic neutrophilic leukemia
  • essential thrombocythemia
  • polycythemia vera
  • Waldenstrom macroglobulinemia
  • extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  • nodal marginal zone B-cell lymphoma
  • recurrent adult Burkitt lymphoma
  • recurrent adult diffuse large cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • recurrent adult lymphoblastic lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent mantle cell lymphoma
  • recurrent marginal zone lymphoma
  • recurrent small lymphocytic lymphoma
  • splenic marginal zone lymphoma
  • recurrent childhood grade III lymphomatoid granulomatosis
  • childhood nasal type extranodal NK/T-cell lymphoma
  • recurrent childhood large cell lymphoma
  • childhood diffuse large cell lymphoma
  • childhood immunoblastic large cell lymphoma
  • recurrent childhood lymphoblastic lymphoma
  • Burkitt lymphoma
  • recurrent childhood small noncleaved cell lymphoma
  • anaplastic large cell lymphoma
  • angioimmunoblastic T-cell lymphoma
  • recurrent adult T-cell leukemia/lymphoma
  • recurrent adult grade III lymphomatoid granulomatosis
  • adult nasal type extranodal NK/T-cell lymphoma
  • recurrent adult Hodgkin lymphoma
  • recurrent/refractory childhood Hodgkin lymphoma
  • refractory chronic lymphocytic leukemia
  • refractory multiple myeloma
  • stage III multiple myeloma
  • aplastic anemia
  • paroxysmal nocturnal hemoglobinuria
  • adult acute lymphoblastic leukemia in remission
  • childhood acute lymphoblastic leukemia in remission
  • recurrent cutaneous T-cell non-Hodgkin lymphoma
  • recurrent mycosis fungoides/Sezary syndrome
  • stage II multiple myeloma
04

Who can participate

Ages eligible
0 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of one of the following:

    • Acute lymphocytic leukemia (ALL), meeting one of the following criteria:

      • In first relapse or beyond
      • High-risk ALL, defined by any of the following:

        • Hypoploidy (≤ 44 chromosomes)
        • Pseudodiploidy with translocations or molecular evidence of t(9;22), 11q23, or t(8;14), excluding B-cell ALL
        • Elevated WBC at presentation (WBC > 20,000/mm³ [for patients > 18 years of age]; WBC > 200,000/mm³ [for patients 12-18 years of age])
    • Acute myeloid leukemia (AML), meeting one of the following criteria:

      • In first complete remission
      • Failed to achieve remission
      • In first relapse or beyond
      • Secondary AML (> 30% blasts in marrow aspirate)

        • Should receive induction chemotherapy to obtain remission, if possible, before transplant
    • Chronic myelogenous leukemia, meeting one of the following criteria:

      • In first or second chronic phase or accelerated phase
      • In blast crisis, defined as > 30% promyelocytes plus blasts in the bone marrow
    • Myelodysplastic syndromes, including any of the following:

      • anemia with excess blasts (RAEB)
      • Chronic myelomonocytic leukemia
      • RAEB in transformation
    • Refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, or multiple myeloma

      • Received and failed front-line therapy, high-dose therapy and stem cell transplantation, or salvage therapy
    • Myeloproliferative disorders/myelofibrosis may be allowed on a case by case basis
    • Severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, or any other hematologic disorder requiring transplantation
  • Patients > 55 years of age with hematologic diseases treatable by allogeneic stem cell transplantation who are not eligible for IRB 99190 are eligible
  • No uncontrolled CNS involvement of disease
  • No matched (6/6) related donor available
  • HLA-identical unrelated donor available

    • HLA-phenotypically identical for HLA-A and HLA-B alleles and identical for DRB1 alleles by DNA typing for both class I and class II antigens

      • Allele mismatch for HLA class I (i.e., B 2701 vs B 2702) allowed if no alternative donors
      • Allele mismatch for class II (i.e., DRB1 0401 vs 0402) or minor mismatch for class I cross reactive group (CREG) (i.e., A 2 vs A 28) allowed in patients ≤ 35 years of age requiring urgent transplant

PATIENT CHARACTERISTICS:

  • performance status 50-100%
  • > 8 weeks
  • ≥ 45% at rest
  • ≤ 2 times normal (unless liver function abnormality is due to underlying disease)
  • Total \< 1.5 times normal (unless liver function abnormality is due to underlying disease)
  • Creatinine ≤ 1.5 times normal OR ≥ 60 mL/min
  • DLCO ≥ 40% of predicted (corrected for )
  • No coexisting medical problem that would significantly increase the risk of the transplant procedure
  • negative
  • Not pregnant

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    Regimen I

    Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.

    Drug: cyclophosphamide · Drug: cyclosporine · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation

  • Active comparator
    Regimen II

    Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.

    Drug: busulfan · Drug: cyclophosphamide · Drug: cyclosporine · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation

  • Active comparator
    Regimen III

    Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.

    Drug: cyclosporine · Drug: etoposide · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation

  • Active comparator
    Regimen IV

    Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.

    Drug: cyclosporine · Drug: fludarabine phosphate · Drug: melphalan · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation

  • Active comparator
    Regimen V

    Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.

    Drug: cyclosporine · Drug: fludarabine phosphate · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation

  • Active comparator
    Regimen VI

    Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.

    Drug: busulfan · Drug: cyclosporine · Drug: fludarabine phosphate · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation

Interventions

06

What researchers measure

Primary outcomes

  1. Neutrophil Engraftment - The Days Till ANC Recovery

    The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.

    Time frame: Up to 180 days post transplant

Secondary outcomes

  1. Two-year Overall Survival

    Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.

    Time frame: Up to 2 years post transplant

07

Results

Posted May 10, 2023

Participant flow

Among the 260 enrolled patients, who consented to the study, 5 patients were not eligible.

Participant flow — Overall Study
MilestoneRegimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VI
Started62171304402
Completed62171304402
Not completed000000

Outcome measures

PrimaryNeutrophil Engraftment - The Days Till ANC Recovery

The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.

Time frame:
Up to 180 days post transplant
Reported as:
Median · days
Neutrophil Engraftment - The Days Till ANC Recovery
daysRegimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VI
Neutrophil Engraftment - The Days Till ANC Recovery17 (11 to 39)16 (13 to 21)15 (8 to 36)14 (14 to 17)18 (11 to 28)16 (16 to 16)
SecondaryTwo-year Overall Survival

Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.

Time frame:
Up to 2 years post transplant
Reported as:
Number · percentage of survival probability
Two-year Overall Survival
percentage of survival probabilityRegimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VI
Two-year Overall Survival58 (45 to 69)50 (25 to 71)54 (45 to 62)50 (6 to 84)38 (23 to 52)50 (0.1 to 91)

Adverse events

Collected over Adverse events were assessed up to Day 100 post-transplant. All-Cause Mortality was assessed from start of protocol treatment to death due to any cause, or last follow-up, whichever comes first, assessed up to 20 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen I45/62 (72.6%)4/62 (6.5%)14/62 (22.6%)
Regimen II14/17 (82.4%)1/17 (5.9%)4/17 (23.5%)
Regimen III103/130 (79.2%)7/130 (5.4%)38/130 (29.2%)
Regimen IV2/4 (50%)0/4 (0%)0/4 (0%)
Regimen V32/40 (80%)3/40 (7.5%)10/40 (25%)
Regimen VI1/2 (50%)1/2 (50%)1/2 (50%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventRegimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VI
Infection with unknown ANCInfections and infestations1/620/172/1300/41/401/2
Infection without neutropeniaInfections and infestations1/620/171/1300/41/401/2
Neuropathy: motorNervous system disorders1/621/170/1300/40/400/2
HypoxiaRespiratory, thoracic and mediastinal disorders1/620/174/1300/42/400/2
PlateletsBlood and lymphatic system disorders2/620/170/1300/40/400/2
Supraventricular and nodal arrhythmiaCardiac disorders2/620/170/1300/41/400/2
Bilirubin associated with GVHD for BMT studies, if specified in the protocol.Hepatobiliary disorders2/620/170/1300/41/400/2
Muscle weakness, generalized or specific area (not due to neuropathy)Musculoskeletal and connective tissue disorders2/620/170/1300/40/400/2
Somnolence/depressed level of consciousnessNervous system disorders2/620/171/1300/40/400/2
Rash/desquamation associated with GVHD for BMT studies, if specified in the protocol.Skin and subcutaneous tissue disorders2/620/170/1300/40/400/2
Most frequent other events
Showing 10 of 163
Most frequent other events
EventRegimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VI
HypertensionCardiac disorders3/621/177/1300/40/401/2
ALT, SGPT (serum glutamic pyruvic transaminase)Investigations5/622/1712/1300/42/401/2
Sodium, serum-low (hyponatremia)Investigations3/620/1711/1300/40/401/2
Acute graft versus host disease (GVHD) (COH)Investigations4/620/1719/1300/42/400/2
Graft versus host diseaseInvestigations3/620/1717/1300/42/400/2
Glucose, serum-high (hyperglycemia)Investigations6/621/1712/1300/45/400/2
Renal failureRenal and urinary disorders0/622/172/1300/41/400/2
Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT studies, if specified in the protocol.Gastrointestinal disorders6/620/1715/1300/43/400/2
Fatigue (asthenia, lethargy, malaise)General disorders4/620/1715/1300/41/400/2
Infection, Bacterial (COH)Infections and infestations3/620/1714/1300/42/400/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VITotal
Median38 (14 to 62)52 (12 to 62)50 (6 to 67)22 (18 to 42)37 (7 to 58)44 (41 to 47)44 (6 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Regimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VITotal
Female2411652171120
Male386652231135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VITotal
American Indian or Alaska Native1000001
Asian20812013
Native Hawaiian or Other Pacific Islander0000000
Black or African American0031004
White55171182382232
More than one race0000000
Unknown or Not Reported4010005
Region of Enrollment
Region of Enrollment(participants)Regimen IRegimen IIRegimen IIIRegimen IVRegimen VRegimen VITotal
United States62171304402255
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2001 to primary completion in Mar 2007, 64 months.

Results were first posted in May 2023, 16 years 1 month after primary completion.

Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's 64 months is below that.

Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2007
First posted
Oct 16, 2007
StartActual
Oct 16, 2001
Primary completionActual
Mar 13, 2007
CompletionEst.
Mar 29, 2027
Results first posted
May 10, 2023
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00544115
Responsible party
Sponsor
First posted
Oct 16, 2007
Start date
Oct 16, 2001
Primary completion
Mar 13, 2007
Completion
Mar 29, 2027 (estimated)
Results posted
May 10, 2023
Last update
Jun 2, 2026

Study contacts

Auayporn P. Nademanee, MD
study chair · City of Hope Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Cyclophosphamide · Etoposide · Fludarabine phosphate · Melphalan

Start the discussion